The Journal of clinical endocrinology and metabolism · 2026
Oxytocin-induced changes in free T3/free T4 ratio and relationship with quality of life in adults with obesity.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Galbiati Francesca, Wronski Marie-Louis, Bitar Thomas, Bikas Athanasios, Lamont Hannah, Hiranandani Sarah, Holman Katherine, Eddy Kamryn T, Asanza Elisa, Smith Sarah, Muhammed Maged, Plessow Franziska, Aulinas Anna, Lawson Elizabeth A
Аннотация
CONTEXT: Oxytocin (OXT) is an anorexigenic, anxiolytic, and antidepressant neurohormone under investigation for obesity treatment. Mechanisms underlying OXT psychological effects are not fully understood, and human data on OXT modulation of the thyroid axis are lacking. Our 8-week trial of intranasal OXT in adults with obesity showed improved mental health-related quality of life (MHQoL) measured by the Short-Form 36 Health Survey vs placebo. Increased T4 and decreased T3 have been linked to depression. The free (bioactive) T3 (fT3)/free T4 (fT4) ratio, a marker of thyroid function in euthyroid patients, is associated with improved mental health.
OBJECTIVE: To determine whether 6 weeks of intranasal OXT vs placebo modulates (1) the thyroid axis and (2) the relationship between fT3/fT4 and MHQoL changes.
DESIGN: Eight-week randomized clinical trial, secondary analysis.
SETTING: Tertiary academic center.
PARTICIPANTS: Sixty-one adults with obesity.
INTERVENTIONS: Eight weeks of intranasal OXT (24 IU) 4× daily or placebo.
MAIN OUTCOME MEASURES: Pre- and posttreatment fasting thyroid hormones (week 6) and MHQoL (week 8).
RESULTS: Six weeks of intranasal OXT vs placebo impacted fT3/fT4 (treatment × time P = .045), with an increase in the OXT group (P = .048) and no change in the placebo group (P = .406). TSH, fT4, and fT3 did not change (P ≥ .154). OXT vs placebo impacted the relationship between fT3/fT4 (6 weeks) and MHQoL (8 weeks) changes (treatment × Δ[fT3/fT4] P = .023); increased fT3/fT4 was positively associated with MHQoL improvement (trend-level P = .088).
CONCLUSION: Prolonged OXT vs placebo increased fT3/fT4 and impacted the relationship between fT3/fT4 and MHQoL changes, with a trend-level positive correlation between fT3/fT4 and MHQoL change scores. OXT action on fT3/fT4 may underpin OXT-induced mental health benefits.
CLINICAL TRIAL REGISTRATION: NCT03043053.
OBJECTIVE: To determine whether 6 weeks of intranasal OXT vs placebo modulates (1) the thyroid axis and (2) the relationship between fT3/fT4 and MHQoL changes.
DESIGN: Eight-week randomized clinical trial, secondary analysis.
SETTING: Tertiary academic center.
PARTICIPANTS: Sixty-one adults with obesity.
INTERVENTIONS: Eight weeks of intranasal OXT (24 IU) 4× daily or placebo.
MAIN OUTCOME MEASURES: Pre- and posttreatment fasting thyroid hormones (week 6) and MHQoL (week 8).
RESULTS: Six weeks of intranasal OXT vs placebo impacted fT3/fT4 (treatment × time P = .045), with an increase in the OXT group (P = .048) and no change in the placebo group (P = .406). TSH, fT4, and fT3 did not change (P ≥ .154). OXT vs placebo impacted the relationship between fT3/fT4 (6 weeks) and MHQoL (8 weeks) changes (treatment × Δ[fT3/fT4] P = .023); increased fT3/fT4 was positively associated with MHQoL improvement (trend-level P = .088).
CONCLUSION: Prolonged OXT vs placebo increased fT3/fT4 and impacted the relationship between fT3/fT4 and MHQoL changes, with a trend-level positive correlation between fT3/fT4 and MHQoL change scores. OXT action on fT3/fT4 may underpin OXT-induced mental health benefits.
CLINICAL TRIAL REGISTRATION: NCT03043053.